

Prostate cancer epidemiology in the United States

World Journal of Urology

30, 195-200

DOI: [10.1007/s00345-012-0824-2](https://doi.org/10.1007/s00345-012-0824-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Trends in Prostate Cancer in the United States. Journal of the National Cancer Institute Monographs, 2012, 2012, 152-156.	0.9	173
3	Integrin α 5 β 3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF- κ B ligand signaling axis. Molecular Cancer, 2012, 11, 66.	7.9	70
4	Prostate cancer epidemiology in the United States. World Journal of Urology, 2012, 30, 195-200.	1.2	271
5	Early Detection of Prostate Cancer: AUA Guideline. Journal of Urology, 2013, 190, 419-426.	0.2	945
6	Prostate cancer incidence and survival in immigrants to Sweden. World Journal of Urology, 2013, 31, 1483-1488.	1.2	9
7	A Low Dietary Ratio of Omega-6 to Omega-3 Fatty Acids May Delay Progression of Prostate Cancer. Nutrition and Cancer, 2013, 65, 556-562.	0.9	35
8	â€Raceâ€™ and Prostate Cancer Mortality in Equal-access Healthcare Systems. American Journal of Medicine, 2013, 126, 1084-1088.	0.6	47
9	<scp>A</scp>merican <scp>U</scp>rological <scp>A</scp>ssociation (<scp>AUA</scp>) Guideline on prostate cancer detection: process and rationale. BJU International, 2013, 112, 543-547.	1.3	114
10	Translation of human African trypanosomiasis biomarkers towards field application. Translational Proteomics, 2013, 1, 12-24.	1.2	7
11	An appraisal of the therapeutic value of lycopene for the chemoprevention of prostate cancer: A nutrigenomic approach. Food Research International, 2013, 54, 1217-1228.	2.9	14
12	Locally Advanced Prostate Cancer: Optimal Therapy in Older Patients. Drugs and Aging, 2013, 30, 959-967.	1.3	3
13	Management of Biochemical Recurrence After Primary Treatment of Prostate Cancer: A Systematic Review of the Literature. European Urology, 2013, 64, 905-915.	0.9	128
14	Gene Panel Model Predictive of Outcome in Patients with Prostate Cancer. OMICS A Journal of Integrative Biology, 2013, 17, 407-413.	1.0	3
15	Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population. Journal of Urology, 2013, 190, 2047-2053.	0.2	280
16	The association between overall survival of prostate cancer patients and hypertension, hyperglycemia, and overweight in Southern China: a prospective cohort study. Journal of Cancer Research and Clinical Oncology, 2013, 139, 943-951.	1.2	14
17	Effect of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of prostate cancer patients. Chinese-German Journal of Clinical Oncology, 2013, 12, 188-193.	0.1	3
18	Prostate Cancer and the Increasing Role of Active Surveillance. Postgraduate Medicine, 2013, 125, 109-116.	0.9	7
19	HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification. Clinical Cancer Research, 2013, 19, 1400-1410.	3.2	51

#	ARTICLE	IF	CITATIONS
20	GSTT1Null Genotype Is Associated with an Increased Risk of Prostate Cancer in Caucasians: A Meta-Analysis. <i>Urologia Internationalis</i> , 2013, 91, 113-120.	0.6	1
21	Phosphorylation of NuMA by AuroraA kinase in PC prostate cancer cells affects proliferation, survival, and interphase NuMA localization. <i>Journal of Cellular Biochemistry</i> , 2013, 114, 823-830.	1.2	19
22	Case-control and prospective studies of dietary linolenic acid intake and prostate cancer risk: a meta-analysis. <i>BMJ Open</i> , 2013, 3, e002280.	0.8	14
23	Utilization of Prostate Cancer Screening According to Dietary Patterns and Other Demographic Variables. The Adventist Health Study-2. <i>Journal of Cancer</i> , 2013, 4, 416-426.	1.2	10
24	When to perform positron emission tomography/computed tomography or radionuclide bone scan in patients with recently diagnosed prostate cancer. <i>Cancer Management and Research</i> , 2013, 5, 123.	0.9	6
25	Comprehensive microRNA Profiling of Prostate Cancer. <i>Journal of Cancer</i> , 2013, 4, 350-357.	1.2	194
26	Non-Androgen Regulated Transcription Factors as Novel Potential Targets for Prostate Cancer Therapy. , 0, , .		0
27	Prostate-Specific Antigen testing in men between 40 and 70 years in Brazil: database from a check-up program. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2014, 40, 745-752.	0.7	2
28	Functional status declines among cancer survivors: Trajectory and contributing factors. <i>Journal of Geriatric Oncology</i> , 2014, 5, 359-367.	0.5	67
29	Development and validation of a prognostic index for fracture risk in older men undergoing prostate cancer treatment. <i>Journal of Geriatric Oncology</i> , 2014, 5, 343-351.	0.5	5
30	Prostate cancer and occupational exposure to whole-body vibration in a national population-based cohort study. <i>American Journal of Industrial Medicine</i> , 2014, 57, 896-905.	1.0	12
31	Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer. <i>BJU International</i> , 2014, 113, E98-105.	1.3	11
32	Does mechanical bowel preparation ameliorate damage from rectal injury in radical prostatectomy? Analysis of 151 rectal injury cases. <i>International Journal of Urology</i> , 2014, 21, 566-570.	0.5	12
33	Screening for Prostate Cancer With the Prostate-Specific Antigen Test. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1143.	3.8	296
34	A critical review of the epidemiology of Agent Orange/TCDD and prostate cancer. <i>European Journal of Epidemiology</i> , 2014, 29, 667-723.	2.5	34
35	Black and White men younger than 50 years of age demonstrate similar outcomes after radical prostatectomy. <i>BMC Urology</i> , 2014, 14, 98.	0.6	12
36	Magnetic Resonance Perfusion Characteristics of Hypervascular Renal and Hypovascular Prostate Spinal Metastases. <i>Spine</i> , 2014, 39, E1433-E1440.	1.0	31
37	Diagnostic Accuracy of 18F Choline PET/CT using Time-of-Flight Reconstruction Algorithm in Prostate Cancer Patients With Biochemical Recurrence. <i>Clinical Nuclear Medicine</i> , 2014, 39, e197-e201.	0.7	13

#	ARTICLE	IF	CITATIONS
38	Single-Cell Genetic Analysis Reveals Insights into Clonal Development of Prostate Cancers and Indicates Loss of PTEN as a Marker of Poor Prognosis. <i>American Journal of Pathology</i> , 2014, 184, 2671-2686.	1.9	29
39	A Novel Role for Raloxifene Nanomicelles in Management of Castrate Resistant Prostate Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	14
41	The Impact of Recent Screening Recommendations on Prostate Cancer Screening in a Large Health Care System. <i>Journal of Urology</i> , 2014, 191, 1737-1742.	0.2	53
42	Additional value of PCA3 density to predict initial prostate biopsy outcome. <i>World Journal of Urology</i> , 2014, 32, 917-923.	1.2	8
43	Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 657-671.	2.7	49
44	Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer. <i>Contrast Media and Molecular Imaging</i> , 2014, 9, 211-220.	0.4	57
45	Prostate Cancer Biomarkers. <i>Ultrasound Clinics</i> , 2014, 9, 95-98.	0.2	0
47	American Cancer Society prostate cancer survivorship care guidelines. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 225-249.	157.7	324
48	Prostate cancer in young men: an important clinical entity. <i>Nature Reviews Urology</i> , 2014, 11, 317-323.	1.9	206
49	Prognosis Related to Metastatic Burden Measured by ¹⁸ F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2014, 55, 905-910.	2.8	41
50	Sunlight exposure during leisure activities and risk of prostate cancer in Montreal, Canada, 2005-2009. <i>BMC Public Health</i> , 2014, 14, 756.	1.2	6
51	Trajectory of overall health from self-report and factors contributing to health declines among cancer survivors. <i>Cancer Causes and Control</i> , 2014, 25, 1179-1186.	0.8	19
52	Assessment of postoperative quality of life: comparative study between laparoscopic and minimum incision endoscopic radical prostatectomies. <i>International Journal of Clinical Oncology</i> , 2014, 19, 1092-1097.	1.0	4
53	Proteomic Serum Profile of Fatigued Men Receiving Localized External Beam Radiation Therapy for Non-Metastatic Prostate Cancer. <i>Journal of Pain and Symptom Management</i> , 2014, 47, 748-756.e4.	0.6	11
54	1-Stearoylglycerol is associated with risk of prostate cancer: results from a serum metabolomic profiling analysis. <i>Metabolomics</i> , 2014, 10, 1036-1041.	1.4	46
55	Variation in Prostate Cancer Detection Rates in a Statewide Quality Improvement Collaborative. <i>Journal of Urology</i> , 2014, 192, 373-378.	0.2	13
56	Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies. <i>International Urology and Nephrology</i> , 2014, 46, 1715-1728.	0.6	46
57	Blockage of RelB expression by gene silencing enhances the radiosensitivity of androgen-independent prostate cancer cells. <i>Molecular Medicine Reports</i> , 2015, 11, 1167-1173.	1.1	7

#	ARTICLE	IF	CITATIONS
58	Improving the Specificity of the Prostate-specific Antigen Substrate Glutaryl-L-Hyp-Ala-Ser-Chg-Gln as a Promoiety. <i>Chemical Biology and Drug Design</i> , 2015, 86, 837-848.	1.5	6
59	Evaluation of PSMA PET/CT imaging using a ⁶⁸ Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. <i>Nuclear Medicine Communications</i> , 2015, 36, 582-587.	0.5	125
60	Localization and upregulation of survivin in cancer health disparities: a clinical perspective. <i>Biologics: Targets and Therapy</i> , 2015, 9, 57.	3.0	21
61	Current Concepts and Evaluation of Uro-Rectal Diseases by Transrectal Ultrasound: A Review. <i>Advancements in Genetic Engineering</i> , 2015, 04, .	0.1	0
62	Thioredoxin 1 in Prostate Tissue Is Associated with Gleason Score, Erythrocyte Antioxidant Enzyme Activity, and Dietary Antioxidants. <i>Prostate Cancer</i> , 2015, 2015, 1-8.	0.4	8
63	Clinical Predictors of Fatigue in Men With Non-Metastatic Prostate Cancer Receiving External Beam Radiation Therapy. <i>Clinical Journal of Oncology Nursing</i> , 2015, 19, 744-750.	0.3	24
64	Targeting of cytosolic phospholipase A2 \pm impedes cell cycle re-entry of quiescent prostate cancer cells. <i>Oncotarget</i> , 2015, 6, 34458-34474.	0.8	17
65	Metabolic syndrome, dyslipidemia and prostate cancer recurrence after primary surgery or radiation in a veterans cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 190-195.	2.0	22
66	Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha-tocopherol, beta-carotene cancer prevention (ATBC) study. <i>International Journal of Cancer</i> , 2015, 137, 2124-2132.	2.3	133
67	Targeted Prodrug Approaches for Hormone Refractory Prostate Cancer. <i>Medicinal Research Reviews</i> , 2015, 35, 554-585.	5.0	32
68	Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer. <i>British Journal of Cancer</i> , 2015, 112, 755-764.	2.9	62
69	Prostate cancer: The main risk and protective factors—Epigenetic modifications. <i>Annales D'Endocrinologie</i> , 2015, 76, 25-41.	0.6	32
70	Generalizability of established prostate cancer risk variants in men of African ancestry. <i>International Journal of Cancer</i> , 2015, 136, 1210-1217.	2.3	62
71	Differential effect of estradiol and bisphenol A on Set8 and Sirt1 expression in prostate cancer. <i>Toxicology Reports</i> , 2015, 2, 817-823.	1.6	8
72	Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). <i>JAMA Oncology</i> , 2015, 1, 342.	3.4	70
73	Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. <i>Human Molecular Genetics</i> , 2015, 24, 5603-5618.	1.4	50
74	A new optimization method using a compressed sensing inspired solver for real-time LDR-brachytherapy treatment planning. <i>Physics in Medicine and Biology</i> , 2015, 60, 2179-2194.	1.6	14
75	Safety and efficacy of iodine-125 permanent prostate brachytherapy in patients with J-pouch anastomosis after total colectomy for ulcerative colitis. <i>Practical Radiation Oncology</i> , 2015, 5, e437-e442.	1.1	16

#	ARTICLE	IF	CITATIONS
76	Replication and Heritability of Prostate Cancer Risk Variants: Impact of Population-Specific Factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 938-943.	1.1	13
77	Cancer Mortality Reductions Were Greatest Among Countries Where Cancer Care Spending Rose The Most, 1995–2007. <i>Health Affairs</i> , 2015, 34, 562-570.	2.5	22
78	Gleason 6 Prostate Cancer: Translating Biology into Population Health. <i>Journal of Urology</i> , 2015, 194, 626-634.	0.2	75
79	Prostate Cancer Screening and the Associated Controversy. <i>Surgical Clinics of North America</i> , 2015, 95, 1023-1039.	0.5	69
81	Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 69.e29-69.e34.	0.8	8
82	Level-1 Data From the REDUCE Study and the PCPT Data. , 2016, , 199-203.		0
83	A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer. <i>International Journal of Nanomedicine</i> , 2016, 11, 179.	3.3	10
84	Occupational exposure to solar ultraviolet radiation and the risk of prostate cancer. <i>Occupational and Environmental Medicine</i> , 2016, 73, oemed-2016-103567.	1.3	5
85	Novel biomarkers for the detection of prostate cancer. <i>Journal of Clinical Urology</i> , 2016, 9, 3-10.	0.1	24
86	Real-time inverse high-dose-rate brachytherapy planning with catheter optimization by compressed sensing-inspired optimization strategies. <i>Physics in Medicine and Biology</i> , 2016, 61, 5956-5972.	1.6	8
87	In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe. <i>Scientific Reports</i> , 2016, 6, 23314.	1.6	36
88	Salvage external beam radiotherapy for locally recurrent prostate cancer after definitive brachytherapy. <i>Brachytherapy</i> , 2016, 15, 722-729.	0.2	20
89	Inhibition of FOXQ1 induces apoptosis and suppresses proliferation in prostate cancer cells by controlling BCL11A/MDM2 expression. <i>Oncology Reports</i> , 2016, 36, 2349-2356.	1.2	33
90	Linfadenectomía pélvica extendida en pacientes con cáncer de próstata clínicamente localizado: estudio observacional prospectivo. <i>Actas Urológicas Españolas</i> , 2016, 40, 446-452.	0.3	2
91	Pathophysiology of Castration-Resistant Prostate Cancer. , 2016, , 5-22.		1
92	Intake of dietary antioxidants is inversely associated with biomarkers of oxidative stress among men with prostate cancer. <i>British Journal of Nutrition</i> , 2016, 115, 68-74.	1.2	20
93	Extended pelvic lymphadenectomy in patients with clinically localized prostate cancer: A prospective observational study. <i>Actas Urológicas Españolas (English Edition)</i> , 2016, 40, 446-452.	0.2	2
94	Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 617-623.	0.4	12

#	ARTICLE	IF	CITATIONS
95	Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2863-2874.	1.9	37
96	The association between regular use of aspirin and the prevalence of prostate cancer. <i>Medicine (United States)</i> , 2016, 95, e3909.	0.4	6
97	93 A nationwide survey of prostate specific antigen based screening and counseling for prostate cancer. <i>European Urology Supplements</i> , 2016, 15, e93.	0.1	0
98	Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial. <i>Cancer Causes and Control</i> , 2016, 27, 157-164.	0.8	11
99	A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. <i>Biomaterials</i> , 2016, 91, 140-150.	5.7	68
100	No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men. <i>Andrology</i> , 2016, 4, 128-132.	1.9	13
101	Dietary Total Antioxidant Capacity is Inversely Associated with Prostate Cancer Aggressiveness in a Population-Based Study. <i>Nutrition and Cancer</i> , 2016, 68, 214-224.	0.9	23
102	Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI. <i>Nanoscale</i> , 2016, 8, 12668-12682.	2.8	34
103	Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer. <i>Journal of Drug Targeting</i> , 2016, 24, 441-449.	2.1	15
104	A Nationwide Survey of Prostate Specific Antigen Based Screening and Counseling for Prostate Cancer. <i>Urology Practice</i> , 2017, 4, 210-217.	0.2	1
105	Cancer incidence among capacitor manufacturing workers exposed to polychlorinated biphenyls. <i>American Journal of Industrial Medicine</i> , 2017, 60, 198-207.	1.0	11
106	In silico analysis of the deleterious nsSNPs (missense) in the homeobox domain of human <i>HOXB13</i> gene responsible for hereditary prostate cancer. <i>Chemical Biology and Drug Design</i> , 2017, 90, 188-199.	1.5	9
107	The 4Kscore blood test accurately identifies men with aggressive prostate cancer prior to prostate biopsy with or without DRE information. <i>International Journal of Clinical Practice</i> , 2017, 71, e12943.	0.8	24
108	Physicians' Perceptions of Factors Influencing the Treatment Decision-making Process for Men With Low-risk Prostate Cancer. <i>Urology</i> , 2017, 107, 86-95.	0.5	8
109	The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. <i>Nuclear Medicine Communications</i> , 2017, 38, 149-155.	0.5	32
110	Radical Prostatectomy for High-risk Localized or Node-Positive Prostate Cancer: Removing the Primary. <i>Current Urology Reports</i> , 2017, 18, 53.	1.0	7
111	Clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan project. <i>Journal of Epidemiology</i> , 2017, 27, S65-S70.	1.1	11
112	Physician role in physical activity for African-American males undergoing radical prostatectomy for prostate cancer. <i>Supportive Care in Cancer</i> , 2017, 25, 1151-1158.	1.0	10

#	ARTICLE	IF	CITATIONS
113	Prevalence and associations of general practitioners' ordering of 'non-symptomatic' prostate-specific antigen tests: A cross-sectional analysis. <i>International Journal of Clinical Practice</i> , 2017, 71, e12998.	0.8	3
114	Perceptions and knowledge about prostate cancer and attitudes towards prostate cancer screening among male teachers in the Sunyani Municipality, Ghana. <i>African Journal of Urology</i> , 2017, 23, 184-191.	0.1	22
115	Men's experiences after prostatectomy: A meta-synthesis. <i>International Journal of Nursing Studies</i> , 2017, 74, 162-171.	2.5	19
116	The impact of sociodemographic factors and PSA screening among low-income Black and White men: data from the Southern Community Cohort Study. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 424-429.	2.0	19
117	Cancer and Chemoprevention: An Overview. , 2017, , .		2
119	Racial/Ethnic Disparity in Treatment for Prostate Cancer: Does Cancer Severity Matter?. <i>Urology</i> , 2017, 99, 76-83.	0.5	55
120	Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer. <i>Journal of Zhejiang University: Science B</i> , 2017, 18, 921-933.	1.3	14
121	Determinants of behavioral intentions to screen for prostate cancer in Omani men. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2017, 4, 348-355.	0.7	8
122	Stress alters the expression of cancer-related genes in the prostate. <i>BMC Cancer</i> , 2017, 17, 621.	1.1	16
123	Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. <i>Canadian Urological Association Journal</i> , 2017, 11, 16.	0.3	20
124	Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. <i>Journal of Oncology Practice</i> , 2017, 13, e694-e702.	2.5	6
125	Evaluation of ^{99m} Tc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse. <i>Asian Journal of Andrology</i> , 2017, 19, 267.	0.8	29
126	Multiparametric (mp) MRI of prostate cancer. <i>Progress in Nuclear Magnetic Resonance Spectroscopy</i> , 2018, 105, 23-40.	3.9	29
127	Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1106-1112.	1.2	11
128	Clinical comparison of the efficacy of three different bowel preparation methods on the infectious complications following transrectal ultrasonography-guided prostate biopsy in nursing practice. <i>Journal of Clinical Nursing</i> , 2018, 27, 2583-2589.	1.4	6
129	Palliative care needs in hospitalized cancer patients: a 5-year follow-up study. <i>Supportive Care in Cancer</i> , 2018, 26, 181-186.	1.0	13
130	Prostate Specific Antigen Testing after Radical Prostatectomy "Can We Stop at 20 Years?. <i>Journal of Urology</i> , 2018, 199, 114-119.	0.2	7
131	Liquid Biopsy Potential Biomarkers in Prostate Cancer. <i>Diagnostics</i> , 2018, 8, 68.	1.3	9

#	ARTICLE	IF	CITATIONS
132	Role for Growth Regulation by Estrogen in Breast Cancer 1 (GREB1) in Hormone-Dependent Cancers. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2543.	1.8	31
133	Prostate Cancer Screening Trends After United States Preventative Services Task Force Guidelines in an Underserved Population. <i>Health Equity</i> , 2018, 2, 55-61.	0.8	10
134	The Role of Testosterone Therapy in the Setting of Prostate Cancer. <i>Current Urology Reports</i> , 2018, 19, 67.	1.0	18
135	Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population. <i>PLoS ONE</i> , 2018, 13, e0201065.	1.1	30
136	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. <i>Journal of Urology</i> , 2018, 200, 1056-1061.	0.2	2
137	The impact of intra-operative cell salvage during open radical prostatectomy. <i>Translational Andrology and Urology</i> , 2018, 7, S179-S187.	0.6	4
138	Relation between mortality trends of cardiovascular diseases and selected cancers in the European Union, in 1970â€“2017. Focus on cohort and period effects. <i>European Journal of Cancer</i> , 2018, 103, 341-355.	1.3	21
139	HUWE1 upregulation has tumor suppressive effect in human prostate cancer cell lines through c-Myc. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 309-315.	2.5	14
140	The Utility of [18F]DASA-23 for Molecular Imaging of Prostate Cancer with Positron Emission Tomography. <i>Molecular Imaging and Biology</i> , 2018, 20, 1015-1024.	1.3	11
141	National Trend of Uroflowmetry, Urodynamic Study and Cystoscopy Considering the Change in the Population Structure in Korea from 2010 to 2015. <i>Journal of Korean Medical Science</i> , 2018, 33, e145.	1.1	8
142	AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1833-1845.	1.9	36
143	No association of serum PSA with vitamin D or total oxidant-antioxidant capacity in healthy men. <i>Aging Male</i> , 2019, 22, 214-217.	0.9	8
144	Sexual Health Recovery For Prostate Cancer Survivors: The Proposed Role Of Acceptance And Mindfulness-Based Interventions. <i>Sexual Medicine Reviews</i> , 2019, 7, 627-635.	1.5	11
145	Characterization of CD44 intracellular domain interaction with RUNX2 in PC3 human prostate cancer cells. <i>Cell Communication and Signaling</i> , 2019, 17, 80.	2.7	33
146	The role of 18F-fluciclovine PET in the management of prostate cancer: a systematic review and meta-analysis. <i>Clinical Radiology</i> , 2019, 74, 886-892.	0.5	21
147	Diagnostic accuracy of ¹⁸ F flucholine PET/CT for preoperative lymph node staging in newly diagnosed prostate cancer patients; a systematic review and meta-analysis. <i>British Journal of Radiology</i> , 2019, 92, 20190193.	1.0	7
148	Sleep, Shift Work, and Men's Health. , 2019, , 181-206.		0
149	Global incidence of prostate cancer in developing and developed countries with changing age structures. <i>PLoS ONE</i> , 2019, 14, e0221775.	1.1	78

#	ARTICLE	IF	CITATIONS
150	A systematic review and meta-analysis on incidence of prostate cancer in Iran. <i>Health Promotion Perspectives</i> , 2019, 9, 92-98.	0.8	8
151	Safety of testosterone therapy in men with prostate cancer. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1065-1076.	1.0	11
153	Multiple primary malignancies for squamous cell carcinoma and adenocarcinoma of the esophagus. <i>Journal of Thoracic Disease</i> , 2019, 11, 3292-3301.	0.6	13
154	Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries. <i>Cancer Epidemiology</i> , 2019, 59, 51-57.	0.8	14
155	TP53 structural variants in metastatic prostatic carcinoma. <i>PLoS ONE</i> , 2019, 14, e0218618.	1.1	15
156	LncRNA LOXL1/miR-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU145 cells. <i>IUBMB Life</i> , 2019, 71, 1537-1551.	1.5	44
157	Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 231-237.e2.	0.9	21
158	Estimation of tumor and local tissue dose in gold nanoparticles radiotherapy for prostate cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2019, 24, 288-293.	0.3	11
159	Surface Modification of Liposomes by a Lipopolymer Targeting Prostate Specific Membrane Antigen for Theranostic Delivery in Prostate Cancer. <i>Materials</i> , 2019, 12, 756.	1.3	30
160	Germline genetics in localized prostate cancer. <i>Current Opinion in Urology</i> , 2019, 29, 326-333.	0.9	1
161	Does lymph node localization affect prostate-specific membrane antigen uptake?. <i>Nuclear Medicine Communications</i> , 2019, 40, 835-841.	0.5	0
162	Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, 365-376.	0.7	16
163	Androgen receptor expression reduces stemness characteristics of prostate cancer cells (PC3) by repression of CD44 and SOX2. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 2413-2428.	1.2	18
164	The anticancer potential of metformin on prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 351-361.	2.0	63
165	Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis. <i>Urologia Internationalis</i> , 2019, 102, 27-36.	0.6	45
166	Appetite-regulating hormones "leptin, adiponectin and ghrelin" and the development of prostate cancer: a systematic review and exploratory meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 11-23.	2.0	10
167	Dietary inflammatory index and the risk of prostate cancer: a dose-response meta-analysis. <i>European Journal of Clinical Nutrition</i> , 2020, 74, 1001-1008.	1.3	22
168	Mortality Among Men Bearing Prostate Cancer and its Association With Sociodemographic and Clinical Variables / Mortalidade em Homens com Câncer de Próstata e sua Associação com Variáveis Sociodemográficas e Clínicas. <i>Revista De Pesquisa: Cuidado À Fundamental Online</i> , 2020, 11, 648-654.	0.5	2

#	ARTICLE	IF	CITATIONS
169	An increase in prostate cancer diagnosis during inflammatory bowel disease: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 302-309.	0.7	18
170	Mechanisms of decision-making in preoperative assessment for older adult prostate cancer patients: A qualitative study. <i>Journal of Surgical Oncology</i> , 2020, 121, 561-569.	0.8	5
171	Modulation of CXC-motif chemokine receptor 7, but not 4, expression is related to migration of the human prostate cancer cell LNCaP: regulation by androgen and inflammatory stimuli. <i>Inflammation Research</i> , 2020, 69, 167-178.	1.6	9
172	Circulatory and prostatic tissue lipidomic profiles shifts after high-dose atorvastatin use in men with prostate cancer. <i>Scientific Reports</i> , 2020, 10, 12016.	1.6	10
173	Risk and associated factors of depression and anxiety in men with prostate cancer: Results from a German multicenter study. <i>Psycho-Oncology</i> , 2020, 29, 1604-1612.	1.0	7
174	Race differences in mobility status among prostate cancer survivors: The role of socioeconomic status. <i>Advances in Cancer Research</i> , 2020, 146, 103-114.	1.9	11
175	Bone Fracture Incidence After Androgen Deprivation Therapy-Investigational Agents: Results From Cancer Therapy Evaluation Program-Sponsored Early Phase Clinical Trials 2006-2013. <i>Frontiers in Oncology</i> , 2020, 10, 1125.	1.3	3
176	Adolescent dairy product and calcium intake in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study. <i>Cancer Causes and Control</i> , 2020, 31, 891-904.	0.8	9
177	Examining the association of health literacy and numeracy with prostate-related knowledge and prostate cancer treatment regret. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 682.e11-682.e19.	0.8	10
178	Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer. <i>Oncogene</i> , 2020, 39, 5839-5854.	2.6	19
179	Long-term outcomes of incidental prostate cancer at radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 848.e17-848.e22.	0.8	6
180	Mutation <i>HOXB13</i> c.853delT in Martinican prostate cancer patients. <i>Prostate</i> , 2020, 80, 463-470.	1.2	16
181	A discussion on controversies and ethical dilemmas in prostate cancer screening. <i>Journal of Medical Ethics</i> , 2021, 47, 152-158.	1.0	11
182	African-American survivors of prostate cancer: a meta-synthesis of qualitative studies. <i>Journal of Cancer Survivorship</i> , 2021, 15, 40-53.	1.5	1
183	Recommended Definitions of Aggressive Prostate Cancer for Etiologic Epidemiologic Research. <i>Journal of the National Cancer Institute</i> , 2021, 113, 727-734.	3.0	36
184	Local fuzzy geographically weighted clustering: a new method for geodemographic segmentation. <i>International Journal of Geographical Information Science</i> , 2021, 35, 152-174.	2.2	15
185	Impact of statin use on overall and time to biochemical failure following radical prostatectomy or radiation therapy. <i>World Journal of Urology</i> , 2021, 39, 3287-3293.	1.2	3
186	Role of ⁶⁸ Ga-PSMA-PET/CT for the detection of primary prostate cancer prior to biopsy: a prospective study. <i>Central European Journal of Urology</i> , 2021, 74, 315-320.	0.2	3

#	ARTICLE	IF	CITATIONS
187	Dietary Factors and Prostate Cancer Development, Progression, and Reduction. <i>Nutrients</i> , 2021, 13, 496.	1.7	47
188	Incidence and Mortality of Prostate Cancer in Canada during 1992–2010. <i>Current Oncology</i> , 2021, 28, 978-990.	0.9	9
189	Safety, efficacy and cost of intra-operative cell salvage during open radical prostatectomy. <i>Translational Andrology and Urology</i> , 2021, 10, 1241-1249.	0.6	4
190	Knowledge-based inverse treatment planning for low-dose-rate prostate brachytherapy. <i>Medical Physics</i> , 2021, 48, 2108-2117.	1.6	4
192	Propionic Acid-Based PET Imaging of Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2021, 23, 836-845.	1.3	0
193	Racial differences in the treatment and outcomes for prostate cancer in Massachusetts. <i>Cancer</i> , 2021, 127, 2714-2723.	2.0	12
194	The Pathogenesis of Prostate Cancer. , 0, , 29-42.		6
195	An automatic framework for evaluating the vascular permeability of bone metastases from prostate cancer. <i>Physics in Medicine and Biology</i> , 2021, 66, 125006.	1.6	0
196	Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 269-273.	2.0	13
197	Diagnostic Yield of Incremental Biopsy Cores and Second Lesion Sampling for In-Gantry MRI-Guided Prostate Biopsy. <i>American Journal of Roentgenology</i> , 2021, 217, 908-918.	1.0	6
198	Role of Alternative Splicing in Prostate Cancer Aggressiveness and Drug Resistance in African Americans. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1164, 119-139.	0.8	14
199	20-Years of Population-Based Cancer Registration in Hepatitis B and Liver Cancer Prevention in The Gambia, West Africa. <i>PLoS ONE</i> , 2013, 8, e75775.	1.1	14
200	The Association of Fatty Acid Levels and Gleason Grade among Men Undergoing Radical Prostatectomy. <i>PLoS ONE</i> , 2016, 11, e0166594.	1.1	4
201	The predictive efficacy of hypoechoic lesion in ultrasound for prostate cancer in Chinese people: five-year experience in a moderated 10-core transperineal prostate biopsy procedure. <i>Oncotarget</i> , 2017, 8, 79433-79440.	0.8	7
202	Identification of sequence-specific interactions of the CD44-intracellular domain with RUNX2 in the transcription of matrix metalloprotease-9 in human prostate cancer cells. , 2020, 3, 586-602.		6
203	Inhibition of Akt/mTOR Signaling by the Dietary Flavonoid Fisetin. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 995-1001.	0.9	95
204	Detection of Local Recurrence with 3-Tesla MRI After Radical Prostatectomy: A Useful Method for Radiation Treatment Planning?. <i>In Vivo</i> , 2018, 32, 125-131.	0.6	7
205	Prevalence, Cognitive and Socio-Demographic Determinants of Prostate Cancer Screening. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 1041-1046.	0.5	21

#	ARTICLE	IF	CITATIONS
206	Personalized prostate cancer care: from screening to treatment. Asian Journal of Andrology, 2016, 18, 505.	0.8	8
207	A prospective randomized comparative study of targeted versus empirical prophylactic antibiotics in the prevention of infective complications following transrectal ultrasound-guided prostate biopsy. Annals of African Medicine, 2019, 18, 132.	0.2	10
208	Clinicoradiological Profile and Treatment Outcomes in Prostate Cancer at a Tertiary Care Cancer Center in India. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 187-192.	0.1	1
209	Feasibility study of computed vs measured high b-value (1400 s/mm ²) diffusion-weighted MR images of the prostate. World Journal of Radiology, 2014, 6, 374.	0.5	47
210	Survival Rate of Prostate Cancer in Asian Countries: A Systematic Review and Meta-Analysis. Annals of Global Health, 2020, 86, 2.	0.8	32
211	Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Prostate Cancer: a Systematic Review with Meta-analysis. Asian Pacific Journal of Cancer Prevention, 2012, 13, 5665-5669.	0.5	26
212	Prostate Cancer Risk in Relation to a Single Nucleotide Polymorphism in the Insulin-like Growth Factor-binding Protein-3 (IGFBP3) Gene: a Meta-analysis. Asian Pacific Journal of Cancer Prevention, 2012, 13, 6299-6303.	0.5	5
213	Histopathologic Characterization of Prostate Diseases in Madinah, Saudi Arabia. Asian Pacific Journal of Cancer Prevention, 2014, 15, 4175-4179.	0.5	20
214	Selenium and Vitamin E for Prostate Cancer - Justifications for the SELECT Study. Asian Pacific Journal of Cancer Prevention, 2015, 16, 2619-2627.	0.5	17
215	PSA density of the lesion: a mathematical formula that uses clinical and pathological data to predict biochemical recurrence in prostate cancer patients. Revista Do Colegio Brasileiro De Cirurgioes, 2021, 48, e20212965.	0.3	0
216	Prevention of Prostate Cancer. , 2014, , 491-531.		0
217	Gamete/Embryo-Fetal Origins of Tumours. , 2014, , 109-136.		0
219	Prostatakarzinom: Epidemiologie, Ätiologie, Prävention und Früherkennung/Screening. , 2015, , 1-6.		0
220	Prostatakarzinom: Epidemiologie, Ätiologie, Prävention und Früherkennung/Screening. , 2016, , 1301-1304.		0
221	Epidemiology of Aging: Racial/Ethnic Specific Disease Prevalence. , 2017, , 115-144.		0
222	Chapter 7 Neem and Prostate Cancer Therapy. Traditional Herbal Medicines for Modern Times, 2016, , 145-160.	0.1	0
223	Modulation of Akt/mTOR Pathway Signaling by Chemoprevention. , 2017, , 93-103.		0
224	10-Year Experience in Performing Saturation Prostate Biopsy. Revista Universitas Medica, 2017, 57, 430-437.	0.0	0

#	ARTICLE	IF	CITATIONS
225	Analysis of the use of integral combinations of efficacy radical prostatectomy and the evaluation of a new method for the formation of vesico-urethral anastomosis in endoscopic radical prostatectomy in patients with clinically localized prostate cancer. Health of Man, 2017, .	0.1	1
226	Evidence-based approaches to reduce cancer health disparities: Discover, develop, deliver, and disseminate. Journal of Carcinogenesis, 2018, 17, 1.	2.5	1
227	Long-term oncological results of radical prostatectomy in patients with localized prostate cancer. Health of Man, 2018, .	0.1	1
228	Potential Effect of Simvastatin as an Anti-Cancer Agent on SOX7 and SOX9 Expression in Prostate Cancer Cell Lines. Shiraz E Medical Journal, 2018, In Press, .	0.1	1
229	Prostate cancer awareness at Brigham Young University of Idaho: A cross-sectional study. F1000Research, 0, 7, 1714.	0.8	0
230	Carbon nanotubes: versatile nanocarriers for effective delivery of anticancer drugs. , 2019, , 193-225.		0
231	Comparative Analysis of the Sexually Transmitted Pathogens Spectrum in Patients with Benign Hyperplasia and Prostate Cancer. Health of Man, 2019, .	0.1	0
232	Study Results of the 2,3-Diphosphoglycerate Content in Erythrocytes of Patients with Malignant Neoplasm Anemia in Genitourinary Organs Cancer. Ukraïns'kij Å¾urnal Medicini BÅologÅ Ta Sportu, 2021, 0.0 6, 151-157.		1
233	Nanoparticles for Targeting of Prostate Cancer. Current Pharmaceutical Design, 2020, 26, 5393-5413.	0.9	4
234	Comparison of PSA profile with positive prostate cancer pathology and Gleason scores in 2015-2017 in Hamadan. Journal of Research in Urology, 2020, 4, 1-9.	0.0	0
235	Clinical prognosis and gene expression profiles of prostate cancer patients with bone and lymphatic metastases. Food Science and Technology, 0, , .	0.8	0
236	Short-, Intermediate-, and Long-term Quality of Life Outcomes Following Radical Prostatectomy for Clinically Localized Prostate Cancer. Reviews in Urology, 2013, 15, 161-77.	0.9	23
238	Expression and mechanism of action of the SARI tumor suppressor in prostate cancer. International Journal of Clinical and Experimental Pathology, 2015, 8, 7953-60.	0.5	3
239	Oxidative stress measured by thioredoxin reductase level as potential biomarker for prostate cancer. American Journal of Cancer Research, 2015, 5, 2788-98.	1.4	19
240	Vasectomy and the risk of prostate cancer: a meta-analysis of cohort studies. International Journal of Clinical and Experimental Medicine, 2015, 8, 17977-85.	1.3	5
241	Effect of Educational Program based on the Theory of Planned Behavior on Prostate Cancer Screening: A Randomized Clinical Trial. International Journal of Preventive Medicine, 2020, 11, 146.	0.2	1
242	Oncoxin-Viusid may improve quality of life and survival in patients with hormone-refractory prostate cancer undergoing onco-specific treatments. Molecular and Clinical Oncology, 2021, 14, 5.	0.4	2
243	Prostate hyperplasia in St Mary's Hospital Lacor: utility of prostate specific antigen in screening for prostate malignancy. African Health Sciences, 2020, 20, 1259-1263.	0.3	0

#	ARTICLE	IF	CITATIONS
244	Surface-enhanced Raman scattering (SERS) spectroscopy for prostate cancer diagnosis: A review. Photodiagnosis and Photodynamic Therapy, 2022, 37, 102690.	1.3	23
245	Prostate hyperplasia in St Mary's Hospital Lacor: utility of prostate specific antigen in screening for prostate malignancy. African Health Sciences, 2020, 20, 1259-1263.	0.3	1
246	Oncoxin [®] may improve quality of life and survival in patients with hormone-refractory prostate cancer undergoing onco-specific treatments. Molecular and Clinical Oncology, 2020, 14, 1-1.	0.4	3
247	Lower Urinary Tract Symptoms are Common After Artificial Urinary Sphincter Implantation. Urology, 2022, 165, 343-350.	0.5	2
249	Long Non-Coding RNAs at the Chromosomal Risk Loci Identified by Prostate and Breast Cancer GWAS. Genes, 2021, 12, 2028.	1.0	5
250	Damaged Masculinity: How Honor Endorsement Can Influence Prostate Cancer Screening Decision-Making and Prostate Cancer Mortality Rates. Personality and Social Psychology Bulletin, 2023, 49, 296-308.	1.9	5
253	Association of PSA density and Gleason score of the positive surgical margin with biochemical recurrence in prostate cancer; a historical cohort study. Urologia, 0, , 039156032211040.	0.3	0
256	An Online Doctor's and Patient help Desk Assistant for Early Diagnoses of Prostate Cancer in the Rural Areas of Bayelsa State. International Journal of Scientific Research in Computer Science Engineering and Information Technology, 2022, , 122-129.	0.2	0
257	PRState: Incorporating genetic ancestry in prostate cancer risk scores for men of African ancestry. BMC Cancer, 2022, 22, .	1.1	0
258	AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer. Oncogenesis, 2023, 12, .	2.1	4
259	Numerical convergence and stability analysis for a nonlinear mathematical model of prostate cancer. Numerical Methods for Partial Differential Equations, 2023, 39, 3064-3088.	2.0	0
260	Statistical Data (1978-2020) on Prostate Cancer in the Southern Population of Mexico. Clinical Cancer Investigation Journal, 2023, 12, 7-10.	0.2	1
261	Applying recommended definition of aggressive prostate cancer: a validation study using high-quality data from the Cancer Registry of Norway. Acta Oncologica, 2023, 62, 8-14.	0.8	0
262	Analysis of Frailty Syndrome in Men with Metastatic Prostate Cancer: A Scoping Review. Journal of Personalized Medicine, 2023, 13, 319.	1.1	2
263	Disease burden of prostate cancer from 2014 to 2019 in the United States: estimation from the Global Burden of Disease Study 2019 and Medical Expenditure Panel Survey. Epidemiology and Health, 0, 45, e2023038.	0.8	0